logo
Share SHARE
FONT-SIZE Plus   Neg

NewLink Genetics Reveals Positive Results From Its Phase-2 Immunotherapy Trial

NewLink Genetics Corporation (NLNK) Monday revealed then results of its 0ne-year, two-year and three-year overall survival data from its Phase-2 HyperAcute Pancreas Immunotherapy trial.

The multi-institutional, open-label, dose-finding, Phase 2 trial evaluated the use of algenpantucel-L in addition to chemotherapy with chemoradiotherapy in the adjuvant setting for resected pancreatic cancer.

The company stated that the study results show 37%, 59% and 121% improvement in 1-, 2- and 3-year survival, respectively, as compared to standard-of-care.

The company stated that the primary endpoint of the study, 12-month disease free survival (DFS), was 62%. The median DFS was 14.1 months. Subgroup analysis showed that patients receiving 300 million cells/dose had a 12-month DFS of 81%, while those receiving 100 million cells/dose had a 12-month DFS of 51%.

The results of the trial revealed that the Overall 12-month survival was 86%. The predicted 12 month overall survival in our study was 63%. Subgroup analysis showed that patients receiving 300 million cells/dose had an overall 12-month survival of 96%, while those receiving 100 million cells/dose had an overall 12-month survival of 79%. Two-year overall survival in our study was 51% with a predicted survival of 32% and 3-year overall survival was 42% with a predicted survival of 19%.

NewLink Genetics further added that the HyperAcute Pancreas immunotherapy product candidate, also referred to as algenpantucel-L, demonstrated good tolerability and a favorable safety profile with no grade four adverse events considered attributable to the immunotherapy.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Aerospace and defense giant Boeing Co. on Wednesday reported a turnaround to profit in the second quarter as lower revenues were more than offset by a decline in costs and expenses. Adjusted earnings per share beat analysts' expectations, while revenues missed their estimates. Looking ahead to fiscal 2017, the company raised its outlook for earnings. Coca-Cola Company (KO) reported a profit for the second-quarter 2017 that declined 60 percent from the prior year, as the company incurred a charge of $653 million related to refranchising its North America bottling operations. The company reaffirmed full year underlying performance outlook, but raised full year comparable earnings per share target on diminished currency headwinds. Ford Motor Company (F) reported second-quarter adjusted EPS of $0.56, up $0.04 year over year. On average, 21 analysts polled by Thomson Reuters expected the company to report profit per share of $0.43 for the quarter. Analysts' estimates typically exclude special items. However, adjusted pre-tax profit...
comments powered by Disqus
Follow RTT